<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942758</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG26-16</org_study_id>
    <nct_id>NCT02942758</nct_id>
  </id_info>
  <brief_title>Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients &gt;=60 Years With Refractory AML</brief_title>
  <acronym>AML-ViVA</acronym>
  <official_title>Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients &gt;=60 Years With AML Who Are Refractory to Standard Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anticancer Fund, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Regensburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnosis: Acute myeloid leukemia refractory to intensive induction chemotherapy; Age ≥ 60&#xD;
      years, no upper age limit; Study drug: low-dose azacitidine, pioglitazone, ATRA; Safety&#xD;
      Run-In Phase; randomized Phase II, open-label&#xD;
&#xD;
        -  Safety Run-In Phase: Based on a 3 + 3 modified design, the tolerable dose of ATRA for&#xD;
           the randomized phase II is defined.&#xD;
&#xD;
        -  Phase II: Experimental Arm: low-dose azacitidine, pioglitazone, ATRA; Standard Arm:&#xD;
           standard-dose azacitidine; in both arms patients can receive further cycles (with no&#xD;
           limit to the number given) as long as clinically appropriate&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to financial reasons.&#xD;
  </why_stopped>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">March 25, 2020</completion_date>
  <primary_completion_date type="Actual">March 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall Survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission (CR) rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete remission with incomplete blood count recovery (CRi) rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>partial remission (PR) rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematological improvement (HI) rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse (CIR)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of death (CID)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse event free survival (EFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event free survival (EFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QLQ-C30)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and intensity of adverse events (AEs)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>low-dose AZA / ATRA / Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose azacitidine (75 mg/d), ATRA, pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard-dose AZA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard-dose azacitidine (75mg/m²/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose Azacitidine</intervention_name>
    <description>Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle</description>
    <arm_group_label>low-dose AZA / ATRA / Pioglitazone</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 45 mg p.o. continuously from day 1</description>
    <arm_group_label>low-dose AZA / ATRA / Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRA</intervention_name>
    <description>ATRA *45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; *this regimen will be chosen for the first dose to be evaluated.</description>
    <arm_group_label>low-dose AZA / ATRA / Pioglitazone</arm_group_label>
    <other_name>All-trans-retinoic acid; Vesanoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard-dose AZA</intervention_name>
    <description>Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle</description>
    <arm_group_label>standard-dose AZA</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with confirmed diagnosis of acute myeloid leukemia (AML) who are refractory*&#xD;
             to induction therapy and not eligible for further intensive induction therapy based on&#xD;
             documented medical reasons (e.g. disease characteristics or patient characteristics),&#xD;
             or&#xD;
&#xD;
          2. Patients with confirmed diagnosis of acute myeloid leukemia (AML) who are refractory*&#xD;
             to induction therapy and not immediate candidates for allogeneic HSCT (bridge to&#xD;
             transplant is allowed)&#xD;
&#xD;
             *refractory to induction therapy is defined as no CR, no CRi and no PR (according to&#xD;
             standard criteria, see Section 11.2.3) after at least one intensive induction therapy&#xD;
             including at least 5 days of cytarabine 100-200 mg/m² continuously or an equivalent&#xD;
             regimen with cytarabine with total dose not less than 500 mg/m² per cycle and at least&#xD;
             2 days of an anthracycline (e.g. daunorubicin, idarubicin).&#xD;
&#xD;
          3. Age ≥ 60; no upper age limit&#xD;
&#xD;
          4. ECOG performance status of ≤ 2 at screening&#xD;
&#xD;
          5. To control hyperleukocytosis or extramedullary involvement, medication with&#xD;
             hydroxyurea is allowed up to 24h before start of study treatment. In case of&#xD;
             hyperleukocytosis hydroxyurea should be given and start of study treatment should be&#xD;
             delayed until leukocyte counts are &lt; 20 x 10^9/L.&#xD;
&#xD;
          6. Female subjects of childbearing potential* may participate, providing they meet the&#xD;
             following conditions:&#xD;
&#xD;
               -  Have a negative pregnancy test (serum or urine with a sensitivity of at least 25&#xD;
                  mIU/mL; local laboratory) within 72 hours prior to starting study therapy. They&#xD;
                  must agree to ongoing pregnancy testing during the course of the study, and after&#xD;
                  end of study therapy. This applies even if the subject practices true&#xD;
                  abstinence** from heterosexual contact.&#xD;
&#xD;
               -  Agree to practice true abstinence** from heterosexual contact (which must be&#xD;
                  reviewed on a monthly basis) or agree to use, and be able to comply with two&#xD;
                  effective methods of contraception (e.g., oral, injectable, or implantable&#xD;
                  hormonal contraceptive; tubal ligation; intra-uterine device; barrier&#xD;
                  contraceptive with spermicide; or vasectomized partner) without interruption&#xD;
                  during the study therapy (including dose interruptions), and for 3 months after&#xD;
                  discontinuation of study drugs.&#xD;
&#xD;
                    -  A female subject of childbearing potential (FCBP) is a female who: 1) has&#xD;
                       achieved menarche at some point 2) has not undergone a hysterectomy or&#xD;
                       bilateral oophorectomy or 3) has not been naturally postmenopausal&#xD;
                       (amenorrhea following cancer therapy does not rule out childbearing&#xD;
                       potential) for at least 24 consecutive months (ie, has had menses at any&#xD;
                       time in the preceding 24 consecutive months).&#xD;
&#xD;
                         -  True abstinence is acceptable when this is in line with the preferred&#xD;
                            and usual lifestyle of the subject. Periodic abstinence (eg, calendar,&#xD;
                            ovulation, symptothermal, postovulation methods) and withdrawal are not&#xD;
                            acceptable methods of contraception.&#xD;
&#xD;
          7. Male patients with a female partner of childbearing potential must agree to abstain&#xD;
             from sexual intercourse or to the use of at least two effective contraceptive methods&#xD;
             (e.g., synthetic condoms with spermicide, etc) at screening and throughout the course&#xD;
             of the study and should avoid fathering a child during the course of the study and for&#xD;
             3 months following the last study treatment.&#xD;
&#xD;
          8. Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected hypersensitivity to the study drugs and/or any excipients&#xD;
&#xD;
          2. Patients with acute promyelocytic leukemia exhibiting t(15;17)(q22;q12); PML-RARA, or&#xD;
             with variant translocations&#xD;
&#xD;
          3. Acute myeloid leukemia (AML) with isocitratdehydrogenase (IDH) 1 or 2 mutations if&#xD;
             results are available from the central AMLSG reference laboratories&#xD;
&#xD;
          4. ECOG performance status &gt; 2&#xD;
&#xD;
          5. Inadequate cardiac, hepatic and/or renal function at Screening Visit defined as:&#xD;
&#xD;
               1. heart failure NYHA II-IV&#xD;
&#xD;
               2. unstable angina pectoris&#xD;
&#xD;
               3. total bilirubin, ALT, AST &gt; 2.5 x upper normal serum level&#xD;
&#xD;
               4. Creatinine &gt; 1.5 x upper normal serum level&#xD;
&#xD;
          6. Active central nervous system involvement&#xD;
&#xD;
          7. Uncontrolled infection&#xD;
&#xD;
          8. Uncontrolled diabetes mellitus&#xD;
&#xD;
          9. Patients with a &quot;currently active&quot; second malignancy requiring active therapy other&#xD;
             than non-melanoma skin cancers (except for hormonal/antihormonal treatment, e.g. in&#xD;
             prostate or breast cancer)&#xD;
&#xD;
         10. Patients with &quot;currently active&quot; bladder cancer or bladder cancer in their history,&#xD;
             patients with risk factors for bladder cancer (e.g. exposure to aromatic amines or&#xD;
             heavy tobacco smoker), or macrohematuria of unknown origin&#xD;
&#xD;
         11. Severe neurological or psychiatric disorder interfering with ability of giving an&#xD;
             informed consent&#xD;
&#xD;
         12. Known or suspected active alcohol or drug abuse&#xD;
&#xD;
         13. Known positive for HIV, active HBV or HCV infection&#xD;
&#xD;
         14. No consent for registration, storage and processing of the individual disease&#xD;
             characteristics and course as well as information of the family physician and/or other&#xD;
             physicians involved in the treatment of the patient about study participation.&#xD;
&#xD;
         15. Treatment with any other clinical study drug within 14 days before the first&#xD;
             administration of the investigational drugs or at any time during the study&#xD;
&#xD;
         16. Breast feeding woman or women with a positive pregnancy test at Screening Visit&#xD;
&#xD;
         17. Male patients with a female partner of childbearing potential not willing to abstain&#xD;
             from sexual intercourse or to the use of at least two effective contraceptive methods&#xD;
             (e.g., synthetic condoms with spermicide, etc) at screening and throughout the course&#xD;
             of the study and for 3 months following the last study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simone Thomas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Regensburg</investigator_affiliation>
    <investigator_full_name>Simone Thomas</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

